Plain-English translation of NCT03919292 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This clinical trial is studying whether two medications used together— (a cancer-fighting drug) and valproate (a medication that can enhance cancer treatment)—are safe and how well they work against advanced cancers. The study started by testing different doses to find the right combination, and is now expanding to include specific cancer types that have particular genetic mutations. Researchers want to learn whether this medication combination can help patients whose cancers have stopped responding to other treatments.
Many people with advanced cancers run out of standard treatment options, and their disease continues to progress. This medication combination may offer a new approach, particularly for cancers with specific genetic changes that make them resistant to other therapies.
You would take by mouth once daily and valproate by mouth twice daily in 28-day cycles. The study has two phases: an initial phase to determine the safest doses, followed by an expansion phase where eligible patients with specific cancer types receive the recommended doses. You would have regular blood tests and imaging scans to monitor how your cancer responds and track any side effects.
AI-generated summary from trial data · Jul 8, 2026 · Not medical advice
United States
Phase
Safety & dosing / Early efficacy
Sponsor
Virginia Commonwealth University
Collaborators
Puma Biotechnology, Inc.
Enrollment target
~83 participants
Started
May 2019
Primary completion
December 2029
Age range
18 Years and older
Last updated on clinicaltrials.gov in June 2026.